Navigation Links
PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
Date:1/15/2010

RALEIGH, N.C., Jan. 15 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that it will begin providing a client-facing portal into Oracle® Remote Data Capture (RDC) for its early phase studies in its Clinical Pharmacology Units in The Netherlands and the United States. Through the portal, clients working with PRA will have direct access to review RDC data. The portal provides sponsors with the ability to review all entered data, to move between subjects and pages, to see the multiple page views within the system and to compare separate pages in a side-by-side fashion.

Perhaps the most important benefit from this application is improved efficiency in study monitoring. A study monitor can monitor remotely either as a replacement for some site visits or to review data ahead of time in preparation for a site visit. This results in higher quality data and lower study costs through the reduction of monitoring time and queries. Other benefits from this system include the potential for increased client visibility into any potential safety concerns (via live data review) and enhanced communication regarding potential data issues between the client and PRA.

PRA's Early Development Services (EDS) group provides comprehensive services for phase I and phase IIa studies in healthy volunteers or special patient populations. Our expertise is primarily with more complex types of studies in which safety and intelligent design are critical factors.

About PRA International

PRA International conducts clinical trials in more than 75 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in oncology, neurosciences, respiratory/allergy, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials through its 36+ global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.

SOURCE PRA International

RELATED LINKS
http://www.prainternational.com

'/>"/>

SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. On Call International Opens Haiti Earthquake Emergency Hotline
2. International SOS and MediSend to Partner on Humanitarian Healthcare
3. Flu Shots Now Offered in Los Angeles International Airport Terminals
4. Statement by Blue Shield of California CEO Bruce Bodaken Regarding the Groundbreaking for the Family Violence Prevention Funds International Center
5. International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility
6. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
7. AHD International & Funktional Beverages, Inc Launch Red Stuff™ with LuraLean
8. American University of Antigua Becomes First International School to Administer Web-Based NBME Exam
9. Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize
10. Reliv Internationals Carl W. Hastings Elected to Board of the Council for Responsible Nutrition
11. Orameds Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: